Evidence map›Paper›PMID 28694520›Full record

ArticleScientific reports2017

Herbal formula YYJD inhibits tumor growth by inducing cell cycle arrest and senescence in lung cancer.

Tingting Zheng, Zujun Que, Lijing Jiao, Yani Kang, Yabin Gong, Jialin Yao, Chao Ma, Ling Bi, Qihan Dong, Xiaodong Zhao and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. In Vitro and In Vivo Inhibitory Effect of Gujin Xiaoliu Tang in Non-Small Cell Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2018
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Tingting ZhengCancer Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Rd, Shanghai, 200032, China.
Zujun QueCancer Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Rd, Shanghai, 200032, China.
Lijing JiaoInstitute of Clinical Immunology, YueYang Hosptial of Intergrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Rd, Shanghai, 200437, China.
Yani KangSchool of Biomedical Engineering and Bio-ID Center, Shanghai Jiao To ng University, 800 Dongchuan Rd, Shanghai, 200240, China.
Yabin GongDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Rd, Shanghai, 200437, China.
Jialin YaoDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Rd, Shanghai, 200437, China.
Chao MaCancer Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Rd, Shanghai, 200032, China.
Ling BiDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Rd, Shanghai, 200437, China.
Qihan DongEndocrinology Section, Central Clinical School and Charles Perking Center, The University of Sydney, School of Science and Health, The Western Sydney University, Sydney, Australia.
Xiaodong ZhaoSchool of Biomedical Engineering and Bio-ID Center, Shanghai Jiao To ng University, 800 Dongchuan Rd, Shanghai, 200240, China.
Ling XuCancer Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Rd, Shanghai, 200032, China. xulq67@aliyun.com.
Yueyang Hospital · CNShanghai University of Traditional Chinese Medicine · CNShanghai Jiao Tong University · CNWestern Sydney University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer represents a major cause of cancer-related death worldwide. Although various tactics and anti-tumor drugs have been used to improve curative effects, five-year survival rate of lung cancer patients remains poor. In this study, we investigated the action and underlying mechanisms of our recently optimized Chinese herbal formula Yangyinjiedu (YYJD) against lung cancer. YYJD significantly inhibits the proliferation of lung cancer cell lines (95-D, A549, H460 and H1975) by inducing cell cycle arrest and senescence in a dose-dependent manner. In particular, YYJD induces significant G2/M phase arrest and inhibits the colony formation of lung cancer cells. Moreover, we found that administration of YYJD could inhibit the growth of xenografted lung cancer cells in nude mice without loss in body weight. Our findings suggest that the herbal formula YYJD is a potential anti-tumor agent against lung cancer.

Indexed as

A549 CellsAnimalsAntineoplastic Agents, PhytogenicCell CycleCell Line, TumorCell ProliferationCellular SenescenceDNA DamageDose-Response Relationship, DrugHumansLung NeoplasmsMiceMice, NudePlant ExtractsReactive Oxygen SpeciesXenograft Model Antitumor AssaysAntineoplastic Agents, PhytogenicPlant ExtractsReactive Oxygen Species

Identifiers

PMID28694520
PMCPMC5504005
OpenAlexW2725732284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.